Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 113Colorectal Neoplasms 73Stomach Neoplasms 48Pancreatic Neoplasms 45Rectal Neoplasms 40Neoplasms 29Neoplasm Metastasis 29Colonic Neoplasms 18Esophageal Neoplasms 16Triple Negative Breast Neoplasms 13Adenocarcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Gallbladder Neoplasms 9Bile Duct Neoplasms 8Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Liver Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Cholangiocarcinoma 5Breast Neoplasms, Male 5Somatostatinoma 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Gastrointestinal Neoplasms 3Gastrinoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Solid Tumor 2

Interventions

Gemcitabine 4pembrolizumab 2Leucovorin 2Irinotecan 2Fluorouracil 2Albumin-Bound Paclitaxel 24-fluorobenzoyl-TN-14003 2regorafenib 1olaparib 1irinotecan sucrosofate 1ibrutinib 1adavosertib 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Drug Therapy 1Docetaxel 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Pancreatic Adenocarcinoma × Capecitabine × Clear all
NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
47 enrolled 22 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡